Delivery	O
of	O
drugs	B:C0013227
,	O
growth	B:C0018284
factors	I:C0018284
,	O
genes	B:C0017337
and	O
stem	B:C0038250
cells	I:C0038250
via	O
intrapericardial	O
,	O
epicardial	B:C0442016
and	O
intramyocardial	B:C0229984
routes	O
for	O
sustained	O
local	B:C0205276
targeted	B:C2985566
therapy	I:C2985566
of	O
myocardial	B:C0878544
disease	I:C0878544
.	O

Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
(	O
Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
)	O
of	O
therapeutic	B:C1611640
agents	I:C1611640
is	O
a	O
promising	O
strategy	O
that	O
aims	O
to	O
treat	O
various	O
myocardial	B:C1522564
pathologies	O
.	O

It	O
is	O
designed	O
to	O
deliver	O
agents	B:C1611640
directly	O
to	O
the	O
myocardium	B:C0027061
and	O
minimize	O
their	O
extracardiac	B:C0229984
concentrations	O
and	O
side	B:C0041755
effects	I:C0041755
.	O

Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
aims	O
to	O
enhance	O
outcomes	O
of	O
existing	O
therapies	B:C0087111
by	O
broadening	O
their	O
therapeutic	O
window	O
and	O
to	O
utilize	O
new	O
agents	B:C1611640
that	O
could	O
not	O
be	O
otherwise	O
be	O
implemented	O
systemically	O
.	O

This	O
article	B:C0282420
provides	O
a	O
historical	O
overview	O
of	O
six	O
decades	O
Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
evolution	O
in	O
terms	O
of	O
the	O
approaches	O
,	O
including	O
intrapericardial	O
,	O
epicardial	B:C0442016
,	O
and	O
intramyocardial	B:C0229984
delivery	O
,	O
and	O
the	O
wide	O
array	O
of	O
classes	B:C0456387
of	O
agents	B:C1611640
used	O
to	O
treat	O
myocardial	B:C1522564
pathologies	O
.	O

We	O
examine	O
delivery	O
of	O
pharmaceutical	B:C0013227
compounds	I:C0013227
,	O
targeted	B:C0040669
gene	I:C0040669
transfection	I:C0040669
and	O
cell	B:C0087111
implantation	I:C0087111
techniques	I:C0087111
to	O
produce	O
therapeutic	O
effects	O
locally	B:C0205276
.	O

We	O
outline	O
therapeutic	O
indications	O
,	O
successes	O
and	O
failures	B:C0162643
as	O
well	O
as	O
technical	O
approaches	O
for	O
Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
.	O

Expert	O
opinion	O
:	O
While	O
Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
is	O
more	O
complicated	O
than	O
conventional	O
oral	O
or	O
intravenous	O
administration	O
,	O
given	O
recent	O
advances	O
in	O
interventional	O
cardiology	O
,	O
it	O
is	O
safe	O
and	O
may	O
provide	O
better	O
therapeutic	O
outcomes	O
.	O

Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
is	O
complex	O
as	O
many	O
factors	O
impact	O
pharmacokinetics	B:C0031327
and	O
biologic	O
result	O
.	O

The	O
choice	O
between	O
routes	O
of	O
Local	B:C0087111
myocardial	I:C0087111
delivery	I:C0087111
is	O
largely	O
driven	O
not	O
only	O
by	O
the	O
myocardial	B:C1522564
pathology	O
but	O
also	O
by	O
the	O
nature	O
and	O
physicochemical	O
properties	O
of	O
the	O
therapeutic	B:C1611640
agents	I:C1611640
.	O

